For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide derived from cardiac tissue protein analysis, developed by Professor Khavinson's group as the heart-targeted member of the Khavinson bioregulator family. Its published evidence base is entirely preclinical: cell culture studies showing 2 to 5 times upregulation of cytoskeletal proteins and reduced apoptosis markers in fibroblasts, a coronary ligation mouse model reporting threefold mortality reduction, and a rat sarcoma model showing dose-dependent tumor inhibition via vascular disruption. No completed human clinical trials have been published. Unlike Vesugen, which has Russian observational data in cardiovascular patients, Cardiogen has no human clinical data of any kind in indexed literature.
The complete Cardiogen profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use